Drugs / TS-143
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03595202 | Apr → Jul 2017 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03581071 | Oct 2016 → Jul 2017 | chronic kidney disease | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03591133 | Dec 2015 → Apr 2016 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-04-30 | Taisho Pharmaceutical Co., Ltd. | 低酸素誘導因子プロリン水酸化酵素（HIF-PH）阻害剤「TS-143」の全世界における独占的開発・製造・販売権に関する契約締結 taisho.co.jp ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS-143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03581071 ↗ |